AVEO Oncology
AVEO
$15.00
Share price
0.00%
Change (1 day)
170.76%
Change (1 year)
Categories
AVEO Oncology (AVEO) - Cash on Hand
Cash on Hand as of September 2022 : $77.39 M
According to AVEO Oncology
's latest financial reports the company has $77.39 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
AVEO Oncology - Cash on Hand chart (from 2008 to 2022)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2021-12-31 | $87.32 M | 41.39% |
| 2020-12-31 | $61.76 M | 29.36% |
| 2019-12-31 | $47.74 M | 95.46% |
| 2018-12-31 | $24.42 M | -27.14% |
| 2017-12-31 | $33.52 M | 43.59% |
| 2016-12-31 | $23.34 M | -31.6% |
| 2015-12-31 | $34.13 M | -34.74% |
| 2014-12-31 | $52.3 M | -55.86% |
| 2013-12-31 | $0.11 B | -26.21% |
| 2012-12-31 | $0.16 B | -27.37% |
| 2011-12-31 | $0.22 B | 57.73% |
| 2010-12-31 | $0.14 B | 173.29% |
| 2009-12-31 | $51.3 M | 58.51% |
| 2008-12-31 | $32.36 M | -47.58% |
| 2007-12-31 | $61.74 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Eli Lilly LLY | $2.92 B | 3,682.66% | 🇺🇸 USA |
 Amgen AMGN | $10.94 B | 14,039.90% | 🇺🇸 USA |
 Biogen BIIB | $1.04 B | 1,256.49% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | $10.84 B | 13,911.73% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $12.28 B | 15,766.04% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | $18.87 M | -75.61% | 🇺🇸 USA |